Schol et al. describe in this perspective the key role of myeloid effector cells in tumor control during successful immunotherapy. They also discuss myeloid cell tumor-rejecting functions, their intricate interactions with tumor-specific T cells, and highlight strategies to activate them for therapeutic applications.
Hope S. Rugo, MD, FASCO, discusses updated safety findings from the ELEVATE trial of elacestrant-based combinations in ER+/HER2– metastatic breast cancer.
Neil P. Shah, MD, PhD, highlights key recent changes to the CML NCCN guidelines and details anticipated data for 2025.
Strategies nurses and other healthcare professionals can use to help patients with cancer cope with anxiety in inpatient and outpatient settings.
Cancer neuroscience is a rapidly growing multidisciplinary field that conceptualizes tumors as tissues fully integrated into the nervous system. Recognizing the complexity and challenges in…
Azka Ali, MD, discusses findings from the S0221 trial of alternative adjuvant anthracycline and taxane dosing schedules in high-risk, early breast cancer.
The induction regimen of isatuximab plus RVd significantly improved progression-free survival vs RVd alone in transplant-eligible patients with newly diagnosed multiple myeloma.
CM24 plus nivolumab and chemotherapy demonstrated an improvement in efficacy vs chemotherapy alone in metastatic pancreatic ductal adenocarcinoma.
De Jonghe et al. present a comprehensive review of current commercial single-cell and spatial omic technologies, outlining key platforms, methodologies, and trends shaping the field—from microfluidics…
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
